Nonalcoholic fatty liver disease (NAFLD) is characterized by evidence of hepatic steatosis and associates with obesity, diabetes, insulin resistance etc. The spectrum of nonalcoholic fatty liver disease ranges from simple steatosis to nonalcoholic steatohepatitis (NASH). Nonalcoholic steatohepatitis is characterized by inflammation and may progress to fibrosis, resulting in cirrhosis and hepatocellular carcinoma. In recent years, the incidence of NAFLD has increased significantly, which caused a severe economic burden worldwide.

Creative Bioarray has many years of experience in the field of NAFLD and provides pharmacodynamic services for customers to help them assess the efficacy of compounds and study the associated pathological mechanisms through NAFLD model.

Nonalcoholic fatty liver disease models include but not limited to:

• Dietary Models
  • Methionine and Aholine Deficient (MCD) Diet-induced NAFLD Model
  • Choline-Deficient L-Amino Acid-defined Diet-induced NAFLD Model
  • High-Fat Diet-induced NAFLD Model
• Chemical-induced NAFLD Model
  • Carbon Tetrachloride-induced NAFLD Model
• Transgenic Models
  • Lep^ob/Lep^ob (ob/ob) Mice Model